Literature DB >> 2311944

Intraocular penetration of rifampin after oral administration.

K W Wong1, D J D'Amico, B S Oum, P A Baker, K R Kenyon.   

Abstract

Rifampin, the most potent anti-staphylococcal drug known, was examined for its penetration into the aqueous and vitreous of rabbits after a single oral dose of 150 mg, 300 mg, or 600 mg. Maximum levels after the 150 mg dose were achieved at 4 h and were 4.2 micrograms/ml in the aqueous and 2.2 micrograms/ml in the vitreous. After the 300 mg dose, maximum levels were also achieved at 4 h, and were 5.0 micrograms/ml in the aqueous and 2.6 micrograms/ml in the vitreous. The 600 mg dose produced maximum levels at 6 h after administration, with 20.0 micrograms/ml in the aqueous and 15.2 micrograms/ml in the vitreous. These levels exceed the minimum inhibitory concentration for many microorganisms and suggest additional investigation into possible applications of systemic rifampin in the prophylaxis and treatment of bacterial endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311944     DOI: 10.1007/bf02764289

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

1.  Ocular toxicity due to rifampicin.

Authors:  F E Cayley; S K Majumdar
Journal:  Br Med J       Date:  1976-01-24

2.  Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics.

Authors:  L D Sabath; C Garner; C Wilcox; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

Review 3.  Rifampin.

Authors:  B Farr; G L Mandell
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

4.  Combined amphotericin B and rifampin treatment of experimental Candida albicans keratitis.

Authors:  G A Stern; M Okumoto; G Smolin
Journal:  Arch Ophthalmol       Date:  1979-04

Review 5.  Chemical and biological properties of rifampicin.

Authors:  S Furesz
Journal:  Antibiot Chemother       Date:  1970

6.  Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes.

Authors:  W M Scheld; D D Fletcher; F N Fink; M A Sande
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

7.  Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

8.  Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices.

Authors:  G L Archer; M J Tenenbaum; H B Haywood
Journal:  JAMA       Date:  1978-08-25       Impact factor: 56.272

9.  Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease.

Authors:  G H McCracken; C M Ginsburg; T C Zweighaft; J Clahsen
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

10.  Exogenous bacterial endophthalmitis treated without systemic antibiotics.

Authors:  P R Pavan; J H Brinser
Journal:  Am J Ophthalmol       Date:  1987-08-15       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.